Clinical efficacy of coenzyme I combined with sakubatril-valsartan on chronic heart failure:a prospective study

Jiang Yanfen; Tao Lili; Jiang Xinxin

doi:10.3969/j.issn.1674-4055.2023.12.14

Abstract：Objective To investigate the clinical efficacy of coenzyme I combined with sakubatril-valsartan on chronic heart failure(CHF).Methods CHF patients(n=116)were chosen and randomly divided into combined group and control group(each n=58)from the 904th Hospital,Chinese PLA Joint Logistics Support Force from Feb.2021 to Feb.2023.The control group was given sakubatril-valsartan on base of routine treatment,and combined group was additionally given coenzyme I.The clinical efficacy,adverse reactions,heart function related indexes,serum inflammatory indexes,distance of 6-minute walking test(6MWT),scores of Minnesota Living with Heart Failure Questionnaire(MLHFQ)were compared between 2 groups.Results After treatment for 24 weeks,the effective rate was 93.10%in combined group and 79.31%in control group(P＜0.05).The levels of left ventricular end-systolic diameter(LVESD)and left ventricular end-diastolic diameter(LVEDD),scores of MLHFQ,N-terminal pro-brain natriuretic peptide(NT-proBNP),high sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6)and nuclear factor-κB(NF-κB)decreased in 2 groups,and were lower in combined group than those in control group(P＜0.05).The levels of left ventricular ejection fraction(LVEF)and 6MWT distance were promoted in 2 groups,and were higher in combined group than those in control group(P＜0.05).The incidence rates of adverse reactions were 12.07%in combined group and 10.34%in control group,and difference had no statistical significance(P>0.05).Conclusion Coenzyme I combined with sakubatril-valsartan,in treating CHF,can improve heart function,relieve inflammation,improve exercise tolerance and quality of life,and is safe in CHF patients.